Bifosfonatların Pediatrik Nefrolojide Kullanımı Pediatride Bifosfonatlar

1. Graham R, Russell G: Bisphosphonates: Mode of action and
pharmacology. Pediatrics 2007; 119: 150-162
2. Fleisch H: Biphosphonates in osteoporosis. Eur Spine J 2003; 12:
142-146
3. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Langue G, Travers
R: Cyclic administration of pamidronate in children with severe
osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952
4. Glorieux FH: The use of bisphosphonates in children with
osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14:
1491-1495
5. Glorieux FH: Experience with bisphosphonates in osteogenesis
imperfecta. Pediatrics 2007; 119: 163-165
6. Shoemaker LR: Expanding role of bisphosphonate therapy in
children. J Pediatr 1999; 134: 264-267
7. Dunstan CR, Felsenberg D, Seibel MJ: Therapy insight: The risks
and benefits of bisphosphonates for the treatment of tumor-induced
bone disease. Nature Clinical Practice Oncology 2007; 4: 42-55
8. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston
SR: Systematic review of role of bisphosphonates on skeletal
morbidity in metastatic cancer. BMJ 2003; 327: 469-472
9. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE:
Comparison of the effects of intravenous pamidronate and oral
clodronate on symptoms and bone resorption in patients with
metastatic bone disease. Ann Oncol 2001; 12: 1433-1438
10. Inoue Y, Shimojo N, Suzuki S, Arima T, Tomiita M, Minagawa M,
Kohno Y: Efficacy of intravenous alendronate for the treatment of
glucocorticoid-induced osteoporosis in children with autoimmune
diseases. Clin Rheumatol 2008; 27: 909-912
11. Bachrach LK, Ward LM: Clinical review 1: Bisphosphonate use in
childhood osteoporosis. J Clin Endocrinol Metab 2009; 94: 400-409
12. Allgrove J: Biphosphonates. Arch Dis Child 1997; 76: 73-75
13. Rodan GA, Fleisch HA: Bisphosphonates: Mechanisms of action. J
Clin Invest 1996; 97: 2692-2696
14. Odvina CV, Zerwekhe JE, Rao DS, Malouf N, Gottschalk FA, Pak
CY: Severely suppressed bone turnover: A potential complication of
alendronat therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301
15. Lin JH: Bisphosphonates: a review of their pharmacokinetic
properties. Bone 1996; 18: 75-85
139
Yıldız N ve Alpay H: Bifosfonatların Pediatrik Nefrolojide Kullanımı
Pediatride Bifosfonatlar
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
Turk Neph Dial Transpl 2011; 20 (2): 132-141
16. Rodd C: Bisphosphonates in dialysis and transplantation patients:
Efficacy and safety issues. Peritoneal Dialysis International 2001;
21:256-260
17. Tanvetyanon T, Stiff PJ: Management of the adverse effects
associated with intravenous bisphosphonates. Ann Oncol 2006; 17:
897-907
18. Aström E, Söderhäll S: Beneficial effect of long term intravenous
bisphosphonate treatment of osteogenesis imperfecta. Arch Dis
Child 2002; 86: 356-364
19. Papapoulos SE, Cremers SC: Prolonged bisphosphonate release
after treatment in children. N Engl J Med 2007; 356: 1075-1076
20. Acott PD, Wong JA, Crocker JF, Lang B, O’Regan P, Renton KW:
Pamidronate distribution in pediatric renal and rheumatologic
patients. Eur J Clin Pharmacol 2006; 62: 1013-1019
21. Cunningham J: Bisphosphonates in the renal patient. Nephrol Dial
Transplant 2007; 22: 1505-1507
22. Shaw NJ: Management of osteoporosis in children. Eur J Endocrinol
2008; 159: 33-39
23. Munns CFJ, Cowell CT: Prevention and treatment of osteoporosis
in chronically ill children. J Musculoskelet Neuronal Interact 2005;
5: 262-272
24. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH:
Effect of intermittent cyclical etidronate therapy on bone mass and
fracture rate in women with postmenopausal osteoporosis. N Engl J
Med 1990; 322: 1265-1271
25. Steelman J, Zeitler P: Treatment of symptomatic pediatric
osteoporosis with cyclic single-day intravenous pamidronate
infusions. J Pediatr 2003; 142: 417-423
26. Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T,
Horio M, Imai E, Hori M, Ito T: Risedronate, an effective treatment
for glucocorticoid-induced bone loss in CKD patients with or
without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial
Transplant 2007; 22: 1601-1607
27. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama
T, Higashi K, Hyodo N, Yamamoto K, Suzuki S, Miura S: Effect
of risedronate on high-dose corticosteroid-induced bone loss in
patients with glomerular disease. Nephrol Dial Transplant 2007; 22:
1593-1600
28. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T: Effects of
once-weekly oral alendronate on bone in children on glucocorticoid
treatment. Rheumatology 2005; 44: 813–818
29. Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O’Neill TW,
Symmons D:Systematic review of effectiveness of bisphosphonates
in treatment of low bone mineral density and fragility fractures in
juvenile idiopathic arthritis. Arch Dis Child 2006; 91: 753-761
30. Sumník Z, Land C, Rieger-Wettengl G, Körber F, Stabrey
A, Schoenau E: Effect of pamidronate treatment on vertebral
deformity in children with primary osteoporosis. A pilot study using
radiographic morphometry. Horm Res 2004; 61: 137-142
31. Zacharin M: Current advances in bone health of disabled children.
Curr Opin Pediatr 2004; 16: 545-551
32. King W, Levin R, Schmidt R, Oestreich A, Heubi JE: Prevalence of
reduced bone mass in children and adults with spastic quadriplegia.
Dev Med Child Neurol 2003; 45: 12-16
33. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT,
Bachrach SJ: Bisphosphonates to treat osteopenia in children with
quadriplegic cerebral palsy: A randomized, placebo-controlled
clinical trial. J Pediatr 2002; 141: 644-651
34. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni
A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi
ML, Falcini F: Efficacy and safety of alendronate for the treatment
of osteoporosis in diffuse connective tissue diseases in children:
A prospective multicenter study. Arthritis Rheum 2000; 43:
1960-1966
35. Cimaz R, Gattorno M, Sormani MP, Falcini F, Zulian F, Lepore
L, Bardare M, Chiesa S, Corona F, Dubini A, Lenhardt A, Martini
G, Masi L, Bianchi ML: Changes in markers of bone turnover and
inflammatory variables during alendronate therapy in pediatric
patients with rheumatic diseases. J Rheumatol 2002; 29: 1786-1792
36. Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S,
Rogol AD, Wilson TA: Bisphosphonate treatment of pediatric bone
disease. Pediatr Endocrinol Rev. 2005; 3: 87-96
37. Acott PD, Wong JA, Lang BA, Crocker JF: Pamidronate treatment
of pediatric fracture patients on chronic steroid therapy. Pediatr
Nephrol 2005; 20: 368-373
38. Stewart AF: Clinical practice. Hypercalcemia associated with
cancer. N Engl J Med 2005; 352: 373-379
39. Sargent JT, Smith OP: Haematological emergencies managing
hypercalcaemia in adults and children with haematological
disorders. Br J Haematol 2010; 149: 465-477
40. Mathur M, Sykes JA, Saxena VR, Rao SP, Goldman GM: Treatment
of acute lymphoblastic leukemia-induced extreme hypercalcemia
with pamidronate and calcitonin. Pediatr Crit Care Med 2003; 4:
252-255
41. Chatterjee M, Speiser PW: Pamidronate treatment of hypercalcemia
caused by vitamin D toxicity. J Pediatr Endocrinol Metab 2007; 20:
1241-1248
42. Kerdudo C, Aerts I, Fattet S, Chevret L, Pacquement H, Doz F,
Michon J, Garabedian M, Orbach D: Hypercalcemia and childhood
cancer: A 7-year experience. J Pediatr Hematol Oncol 2005; 27: 23-
27
43. Auron A, Tal L, Srivastava T, Alon US: Reversal of hypercalcemic
acute kidney injury by treatment with intravenous bisphosphonates.
Pediatr Nephrol. 2009; 24: 613-617
44. Bereket A, Erdogan T: Oral Bisphosphonate therapy for vitamin D
intoxication of the infant. Pediatrics 2003; 111: 899-901
45. Freundlich M, Alanzo E, Bellorin-Font E, Weisnger JR: Reduced
bone mass in children with idiopathic hypercalciuria and in their
asymptomatic mothers. Nephrol Dial Transplant 2002; 17: 1396-
1401
46. Penido MG, Lima EM, Marino VS, Tupinamba AL, França A, Souto
MF: Bone alterations in children with idiopathic hypercalciuria at
tthe time of diagnosis. Pediatr Nephrol 2002; 18: 133- 139
Yıldız N ve Alpay H: Bifosfonatların Pediatrik Nefrolojide Kullanımı
Pediatride Bifosfonatlar
140 Turk Neph Dial Transpl 2011; 20 (2): 132-141
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
47. Schwaderer AL, Cronin R, Mahan JD, Bates CM: Low bone density
in children with hypercalciuria and/or nephrolithiasis. Pediatr
Nephrol 2008; 23: 2209-2214
48. Weisinger JR: Bone loss in hypercalciuria: Cause or consequence?
Am J Kidney Dis 1999; 33: 46-48
49. Srivastava T, Alon US: Pathophysiology of hypercalciuria in
children. Pediatr Nephrol 2007; 22: 1569-1573
50. Garcia-Nieto V, Ferrandez C, Monge M, de Sequera M, Rodrigo
MD: Bone mineral density in pediatric patients with idiopathic
hypercalciuria. Pediatr Nephrol 1997; 11: 578-583
51. Freundlich M, Alon US: Biphosphonates in children with
hypercalciuria and reduced bone mineral density. Pediatr Nephrol
2008; 23: 2215-2250
52. Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY: Reduced bone
formation and relatively increased bone resorbtion in absorptive
hypercalciuria. Kidney Int 2007; 71: 808-815
53. Hamdy NA, McCloskey EV, Brown CB, Kanis JA: Effects of
clodronate in severe hyperparathyroid bone disease in chronic renal
failure. Nephron 1990; 56: 6-12
54. Ala-Houhala I, Saha H, Liukko-Sipi S, Ylitalo P, Pasternack A:
Pharmacokinetics of clodronate in haemodialysis patients. Nephrol
Dial Transplant 1999; 14: 699-705
55. Beigel AE, Rienhoff E, Olbricht CJ: Removal of clodronate by
haemodialysis in end-stage renal disease patients. Nephrol Dial
Transplant 1995; 10: 2266-2268
56. Saha H, Ala-Houhala IO, Liukko-Sipi SH, Ylitalo P, Pasternack AI:
Pharmacokinetics of clodronate in peritoneal dialysis patients. Perit
Dial Int 1998; 18: 204-209
57. Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P,
Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P,
Wang G, Malluche H: Prevention of bone loss in renal transplant
recipients: A prospective, randomized trial of intravenous
pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676
58. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A,
Kirste G, Olschewski M, Schollmeyer PJ: Treatment of osteopenia
and osteoporosis after kidney transplantation. Transplantation 1998;
66: 1004-1008
59. Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson
CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna
KL, Bia MJ: Treatment of osteoporosis and osteopenia in long-term
renal transplant patients with alendronate. Am J Transplant 2002; 2:
62-67
60. Giannini S, D’Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante
L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi
G: Alendronate prevents further bone loss in renal transplant
recipients. J Bone Miner Res 2001; 16: 2111-2117
61. El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA,
Ghoneim MA: Treatment of osteopenia and osteoporosis in renal
transplant children and adolescents. Pediatr Transplantation 2004:
8: 357–361
62. Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M:
Differences in nephrotoxicity of intravenous bisphosphonates for
the treatment of malignancy-related bone disease. Onkologie 2006;
29: 534-540
63. Jackson GH: Renal safety of ibandronate. Oncologist 2005; 10:
14-18
64. Grenda R, Karczmarewicz E, Rubik J, Matusik H, Płudowski P,
Kiliszek M, Piskorski J: Bone mineral disease in children after
renal transplantation in steroid-free and steroid-treated patients - a
prospective study. Pediatr Transplant 2010; 15(2): 205-213
65. Chang JT, Green L, Beitz J: Renal failure with the use of zoledronic
acid. N Engl J Med 2003; 349: 1676-1679
66. Brumsen C, Hamdy NA, Papapoulos SE: Long-term effects of
bisphosphonates on the growing skeleton. Studies of young patients
with severe osteoporosis. Medicine 1997; 76: 266-283
67. Rauch F, Travers R, Munns C, Glorieux FH: Sclerotic metaphyseal
lines in a child treated with pamidronate: Histomorphometric
analysis. J Bone Miner Res 2004; 19: 1191-1193
68. Klein GL, Bachrach LK, Holm IA: Effects of pharmacologic agents
on bone in childhood: An editorial overview. Pediatrics 2007; 119:
125-130
69. Chan YY, Bishop NJ: Clinical management of childhood
osteoporosis. Int J Clin Pract 2002; 56: 280-286
70. Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL: Characteristics
and bisphosphonate treatment of a patient with juvenile osteoporosis.
J Clin Endocrinol Metab 1985; 61: 952-956
71. Grissom LE, Harcke HT: Radiographic features of bisphosphonate
therapy in pediatric patients. Pediatr Radiol 2003; 33: 226-229
72. Shaw NJ, Bishop NJ: Bisphosphonate treatment of bone disease.
Arch Dis Child 2005; 90: 494-499
73. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A:
Transplacental effects of bisphosphonates on fetal skeletal
ossification and mineralization in rats. Teratology 1999; 60: 68-73
74. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F:
Renal failure associated with intravenous diphosphonates. Lancet
1983; 1:471
75. Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier
S, Biour M, Massy Z: Zoledronic acid and renal toxicity: Data from
French adverse effect reporting database. Ann Pharmacother 2005;
39: 1194-1197
76. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR,
Jagannath S, Kuhn JA, Dratch AD, D’Agati VD: Collapsing focal
segmental glomerulosclerosis following treatment with high-dose
pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172
77. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D:
Short-term, high-dose pamidronate-induced acute tubular necrosis:
The postulated mechanisms of bisphosphonate nephrotoxicity. Am
J Kidney Dis 2003; 41: E18
78. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM,
Wallach J, Walker PD: Podocyte injury associated glomerulopathies
induced by pamidronate. Kidney Int 2004; 65: 634-641
141
Yıldız N ve Alpay H: Bifosfonatların Pediatrik Nefrolojide Kullanımı
Pediatride Bifosfonatlar
Türk N efroloji D iyaliz ve Transplantasyon D ergisi
Turkish Nephrology, Dialysis and Transplantation Journal
Turk Neph Dial Transpl 2011; 20 (2): 132-141
79. Kunin M, Kopolovic J, Avigdor A, Holtzman EJ: Collapsing
glomerulopathy induced by long-term treatment with standard-dose
pamidronate in a myeloma patient. Nephrol Dial Transplant 2004;
19: 723-726
80. Von Moos R: Bisphosphonate treatment recommendations for
oncologists. Oncologist 2005;10: 19-24
81. Högler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT:
Short-term safety assessment in the use of intravenous zoledronic
acid in children. J Pediatr 2004; 145: 701-704
82. Von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R,
Bergstrom B, Schmieding K, Pecherstorfer M: Renal safety profiles
of ibandronate 6 mg infused over 15 and 60 min: A randomized,
open-label study. Ann Oncol 2008; 19: 1266-1270
83. Body JJ, Diel IJ, Tripathy D, Bergstrom B: Intravenous ibandronate
does not affect time to renal function deterioration in patients with
skeletal metastases from breast cancer: Phase III trial results. Eur J
Cancer Care 2006; 15: 299-302
84. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity.
Kidney Int 2008; 74: 1385-1393
85. Munns CF, Rauch F, Mier RJ, Glorieux FH: Respiratory distress
with pamidronate treatment in infants with severe osteogenesis
imperfecta. Bone 2004; 35: 231-234
86. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I,
Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou
C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer
after treatment with bisphosphonates: Incidence and risk factors. J
Clin Oncol 2005; 23: 8580-8587
87. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S:
Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349:
457-463